Your search for dabigatran returned 117 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Your search for dabigatran returned 117 results

Sort Results:

Relevant Recent

Thromboembolic Disorder Assessment: DVT/PE

Risk factors, prevention strategies, signs & symptoms, and general treatment options for deep vein thrombosis (DVT) and pulmonary embolism (PE).

Label Update on Pradaxa Compared to Warfarin

Boehringer Ingelheim announced that the Pradaxa (dabigatran etexilate mesylate capsules) prescribing information has been updated to affirm that Pradaxa 150mg twice daily was superior in reducing ischemic and hemorrhagic strokes relative to warfarin
ASH 2010

Issues in Thrombosis Management and Anticoagulation

Novel oral anticoagulants, that do not require the laboratory monitoring associated with warfarin therapy, may alter the landscape of venous thromboembolism treatment and stroke prevention in atrial fibrillation, according to a study presented at the 52nd American Society of Hematology Meeting and Exposition.

Pradaxa approved for stroke risk reduction

Boehringer Ingelheim announced that the FDA has approved Pradaxa (dabigatran etexilate capsules), an oral direct thrombin inhibitor, to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AFib).